Protinhi Therapeutics, a company specializing in protease inhibition with the aim to combat viral infectious diseases, has announced that it has been selected to join Blue Knight, a global community of early-stage biotech companies. As a Blue Knight company, Protinhi benefits from continuing support and assistance within the JLAB’s (Johnson & Johnson Innovation) global innovation ecosystem.
“Being invited to join the Blue Knight initiative is a significant step in our development. It is fantastic to be working alongside other innovative companies with a shared goal of protecting the world against future health emergencies. We have all seen how the COVID-19 pandemic has affected lives all over the world, so this is an exciting opportunity to be part of a collaborative response,” said Bernd van Buuren, CEO of Protinhi Therapeutics.